SPEAKER_01 0:00

Imagine bleeding heavily for days, uh, finally going to a hematologist to figure out what is wrong and having your blood test come back perfectly normal. Right. And it comes back normal precisely because the severe trauma of your bleeding actually hid the disease from the lab equipment.

SPEAKER_00 0:18

Yeah, it is wild.

SPEAKER_01 0:19

It really is. Welcome to the deep dive. Today we are exploring this really bizarre biological irony and you know the the intense friction between human biology, which exists on this messy, ever-changing continuum, and medical guidelines, which desperately need neat, rigid categories.

SPEAKER_00 0:39

They need boxes.

SPEAKER_01 0:40

Right. They need those check boxes. So we are looking at clinical practice guidelines in von Willebrand disease, and we are anchoring this on William Eyre's recent analysis of how we actually navigate the space.

SPEAKER_00 0:50

Aaron Powell And it is a very tricky space to navigate.

SPEAKER_01 0:52

It is. I mean, most of us, when we think of a medical guideline, we think of it like a GPS turn-by-turn map for doctors. You know, you plug in the symptoms, the computer calculates the row, and you just blindly follow the glowing blue line to a diagnosis.

SPEAKER_00 1:04

Trevor Burrus, Jr.: Take a left at the next symptom.

SPEAKER_01 1:06

Yeah, exactly. But today we are going to see that a medical guideline is actually a lot more like a compass in a thick forest. I mean, it gives you a general direction, sure, and it keeps you from walking in circles, but you still have to actually look at the trees right in front of you.

SPEAKER_00 1:20

Yeah. That is such a great way to frame it. I mean, the tension between having that clear compass direction and, you know, dealing with the tangled reality of the actual forest is pretty much the defining challenge of modern medicine today.

SPEAKER_01 1:33

Absolutely.

SPEAKER_00 1:34

Because medicine is constantly having to balance two really big competing risks. So the first one is just inconsistency. Without a shared set of rules, two patients with the exact same symptoms could walk into two different clinics and receive, frankly, wildly different evaluations and treatments.

SPEAKER_01 1:50

Which is obviously bad. You want the same standard of care.

SPEAKER_00 1:53

Right, exactly. But then the second risk is rigidity. If every single unique complex patient is just forced into predefined, ill-fitting diagnostic boxes based on some rigid algorithm, clinicians are going to completely miss those subtle but clinically really important differences in their underlying biology.

SPEAKER_01 2:13

And to understand why a compass is so much safer than a rigid GPS in this specific scenario, you really have to look at the forest we are navigating today. And that forest is the highly unpredictable biology of von Willebrand factor, or VWF. Yes. So we are talking about the protein in your plasma that basically dictates how well you stop bleeding. And medicine's attempt to write rules for this one specific protein reveals a massive amount about how doctors actually make decisions.

SPEAKER_00 2:42

It really does.

SPEAKER_01 2:43

Because uh VWF is like the ultimate moving target. It is not a fixed personal characteristic, like, say, having type A positive blood.

SPEAKER_00 2:51

No, not at all.

SPEAKER_01 2:52

Right. VWF levels are just constantly fluctuating. They change as you age, they change with intense physical exercise, uh, with systemic inflammation, and even with acute physiological stress.

SPEAKER_00 3:03

And that dynamic nature, the fact that it moves around so much, is exactly why von Willebrand disease uniquely impacts the life course of women.

SPEAKER_01 3:10

Right, because of reproductive biology.

SPEAKER_00 3:12

Exactly. Reproductive physiology repeatedly challenges the body's ability to achieve hemostasis. So for young women, Monarch, you know, getting their first period is often the very first major clinical stress test of their VWF levels. Wow, yeah. Yet you will see a patient experience heavy menstrual bleeding that causes cumulative iron deficiency, profound fatigue, and a significantly reduced quality of life. And the underlying bleeding disorder goes entirely unrecognized.

SPEAKER_01 3:42

Which is just tragic. Why does it get missed so often?

SPEAKER_00 3:44

Well, heavy periods are dangerously normalized within families, for one. People just assume that, well, because their mother and their grandmother experienced heavy bleeding, it is simply a genetic inevitability. Or clinicians incorrectly attribute the bleeding solely to structural gynecologic causes.

SPEAKER_01 4:00

But wait, going back to the physiological stress factor for a second, if VWF protein levels naturally spike when the body is under acute stress or actively bleeding, doesn't that mean the laboratory test could look perfectly normal at the exact moment the patient most needs to know they have a bleeding disorder? Yeah. So if they go to the doctor while they're actively hemorrhaging, aren't they basically masking their own disease?

SPEAKER_00 4:22

That is exactly what happens. It is the cruelest paradox of this disease. So VWF is stored in the endothelial cells that line your blood vessels.

SPEAKER_01 4:31

Okay.

SPEAKER_00 4:32

When the body undergoes the trauma of an active hemorrhage, those cells dump their stored VWF into the bloodstream to try and stop the bleeding.

SPEAKER_01 4:41

Like a panic response.

SPEAKER_00 4:42

Right, exactly like a panic response. So the sudden influx of protein completely obscures the patient's baseline deficiency. The lab result the doctor receives is, I mean, it is merely an observation of a biological moment in time. It is a snapshot. It is not a permanent reflection of the patient's baseline physiology.

SPEAKER_01 5:00

That is so wild that makes the timing of the blood draw almost as important as the blood draw itself.

SPEAKER_00 5:05

It does. And this whole moment in time problem becomes intensely magnified during pregnancy.

SPEAKER_01 5:09

Oh, I bet.

SPEAKER_00 5:10

Yeah, because hemodynamics change drastically during pregnancy, and VWF levels naturally rise to repair the body for childbirth. For patients with type 1 VWD, this physiological rise often masks their quantitative laboratory abnormalities entirely. So they look cured. On paper, yes. Their VWF levels look completely normal in the third trimester. But immediately after delivery, once the biological stress of pregnancy resolves, those levels drop rapidly back to their baseline.

SPEAKER_01 5:41

Oh no. Yeah.

SPEAKER_00 5:43

And this creates a sudden, very high risk for delayed postpartum hemorrhage, often after the patient has already been discharged from the hospital, under the assumption that their clotting function was totally normal.

SPEAKER_01 5:53

Because nature didn't draw a hard biological cliff for this protein. It is just this sliding continuum. But the medical community still had to figure out a way to write a rule book for a biological marker that constantly shifts. Right. You can't just tell doctors, you know, hey, it's a moving target, just use your best judgment. They needed diagnostic thresholds to standardize research, to figure out insurance eligibility, and to allow specialists to actually communicate with each other.

SPEAKER_00 6:18

Exactly. And we can trace how the medical field handled that continuum by looking at the evolution of the guidelines.

SPEAKER_01 6:24

Right. Let's talk about the history a bit.

SPEAKER_00 6:26

So back in 2008, the NHLBI expert panel laid the historical foundation. They formally recognized that bleeding symptoms are highly prevalent in the general population, and no single static test can cleanly rule out VWD.

SPEAKER_01 6:41

Which was a big step.

SPEAKER_00 6:43

It was. But the real shift in how we handle this uncertainty came with the modern 2021 International Diagnosis Guidelines, which heavily utilize what is called the GRADE Framework.

SPEAKER_01 6:54

The GRADE framework.

SPEAKER_00 6:55

Yeah. Grade fundamentally changed the architecture of medical guidelines by explicitly separating two concepts. The first is certainty of evidence, and the second is strength of recommendation.

SPEAKER_01 7:06

Okay, let's unpack GRADE for a second, because this is where medical methodology actually gets really fascinating.

SPEAKER_00 7:10

It really does.

SPEAKER_01 7:11

So think of it like weather forecasting. Certainty of evidence is how mathematically sure the meteorologist is that it is going to rain today based on the radar data. But the strength of recommendation is whether the meteorologist tells you to bring an umbrella. So even if there's only a low certainty, say 20% chance of rain, if you happen to be carrying a priceless water-soluble painting across town, the recommendation to bring an umbrella is incredibly strong.

SPEAKER_00 7:37

I love that analogy. That is spot on. The strength of the recommendation factors in the consequences of being wrong.

SPEAKER_01 7:43

Right. What is at stake?

SPEAKER_00 7:45

Exactly. It relies on the balance of benefits and harms, the resources required, and importantly, patient values. A strong recommendation means almost all informed patients would choose that course of action. However, the guidelines rely heavily on conditional recommendations.

SPEAKER_01 8:03

Conditional meaning, it depends.

SPEAKER_00 8:05

Yes. A conditional recommendation recognizes that reasonable, fully informed patients might choose completely different options based on their specific lived circumstances.

SPEAKER_01 8:14

So it is not just the guideline writers throwing their hands up and saying, well, we just don't know.

SPEAKER_00 8:18

Far from it. I mean, if a treatment requires burdensome, frequent hospital visits to maintain hemostasis, one patient might find that disruption to their life completely unacceptable for just a marginal reduction in bleeding.

SPEAKER_01 8:31

Yeah, that makes sense.

SPEAKER_00 8:32

But another patient with the exact same lab values might find those hospital visits entirely worth it. So the conditional recommendation makes the decision-making process visible, acknowledging that clinical data simply cannot override patient values.

SPEAKER_01 8:46

But if these modern frameworks are designed to be so transparent about uncertainty, what happens when top international experts look at the exact same continuous biology and write rule books that clash?

SPEAKER_00 8:57

Well, that is when things get really heated.

SPEAKER_01 8:59

Because the deeper you look at VWD, the more you run into this massive diagnostic gray zone, which is the whole 30 to 50 debate.

SPEAKER_00 9:05

Right. So we measure VWF levels in international units per deciliter. Generally, lower numbers correlate with a higher bleeding risk.

SPEAKER_01 9:12

Okay.

SPEAKER_00 9:13

The 2014 UK H C DO guideline focused heavily on patients whose levels sit mildly reduced in that gray zone, so between 30 and 50. The UK experts decided to label this range as low VWF.

SPEAKER_01 9:25

Low VWF.

SPEAKER_00 9:26

Right. They viewed it as a bleeding risk factor, much like high blood pressure is a risk factor for a stroke, rather than classifying it as a standalone disease itself.

SPEAKER_01 9:34

But the 2021 International Diagnosis Guideline takes a much harder stance on this.

SPEAKER_00 9:39

They do.

SPEAKER_01 9:39

They state that if a patient's levels are under 50 and they have an established history of abnormal bleeding, they should be officially diagnosed with type 1 BWD. Yes. So the International Guideline calls it a disease, and the UK guideline calls it a risk factor. But honestly, if a patient is bleeding excessively, they need help. I don't really get the controversy here. Why are top medical organizations fighting over a vocabulary word? Shouldn't treat the bleeding take priority over arguing about the name of the condition?

SPEAKER_00 10:09

You would think so, right. But the debate isn't actually about the underlying pathophysiology. Both groups entirely agree on how the protein functions.

SPEAKER_01 10:18

Oh, really?

SPEAKER_00 10:18

Yeah. They're fighting over the massive downstream consequences of a diagnostic label. The disagreement hinges on the competing risk of underdiagnosis versus overdiagnosis.

SPEAKER_01 10:28

Okay, walk me through that.

SPEAKER_00 10:30

Well, labeling someone with VWD immediately improves their access to specialist care. Yeah. It ensures they receive rigorous procedural planning before a surgery, and honestly, it medically validates their lifelong struggle with bleeding. The international guideline prioritizes preserving that access to care.

SPEAKER_01 10:47

Aaron Powell So what is the downside then? If giving them the label gets them the treatment they need, why is the UK so hesitant to call it a disease?

SPEAKER_00 10:56

Because of a cognitive trap known as diagnostic closure.

SPEAKER_01 10:59

Diagnostic closure.

SPEAKER_00 11:00

Right. When a clinician sees the official VWD label in a patient's chart, human nature kind of kicks in. The clinician might start attributing every single bleeding symptom the patient ever has to that slightly low VWF level.

SPEAKER_01 11:13

Oh, so they just stop looking for other stuff.

SPEAKER_00 11:15

Exactly. They stop investigating. They might completely miss an underlying malignancy or a structural gynecologic issue or even a concurrent platelet disorder because they are satisfied with the VWD explanation.

SPEAKER_01 11:27

Wow, that is dangerous.

SPEAKER_00 11:29

It is. Furthermore, attaching a lifelong chronic disease label to a patient affects their medical insurance underwriting. It triggers unnecessary testing anxiety for their family members, and it fundamentally alters the patient's psychological self-image.

SPEAKER_01 11:43

Aaron Powell So the UK guideline is basically trying to prevent tunnel vision. They are saying, let's call it a risk factor so clinicians keep looking for other causes. Right. And the international guideline says, let's call it a disease so insurance companies actually pay for the hematologist.

SPEAKER_00 11:58

Aaron Powell That is the crux of it, yeah.

SPEAKER_01 12:00

Trevor Burrus, it just shows that a lab value between 30 and 50 cannot interpret itself. The numbers are meaningless unless they are filtered through the patient's actual phenotype.

SPEAKER_00 12:09

Right. Their observable lived reality of how their body bleeds and bruises.

SPEAKER_01 12:13

Aaron Powell Which is why the precision of those actual lab numbers is under such intense scrutiny. I mean, if a label carrying that much psychological and logistical weight is decided by a few points on a blood test, the laboratory tools generating those numbers have to be flawless.

SPEAKER_00 12:27

Aaron Ross Powell You would hope so. But as the 2024 UK laboratory guidelines point out, they are far from flawless.

SPEAKER_01 12:34

Not even close.

SPEAKER_00 12:35

No. Interpreting these tests begins long before the blood ever touches the analyzer, during what we call the pre-analytical phase.

SPEAKER_01 12:42

Which means before the lab even gets it.

SPEAKER_00 12:44

Exactly. Something as seemingly minor as a cold transit van transporting the blood vial across town can artificially drop the VWF levels.

SPEAKER_01 12:54

Just because it was chilly in the van?

SPEAKER_00 12:55

Just because of the temperature.

SPEAKER_01 12:56

Yeah.

SPEAKER_00 12:57

Delayed processing ruins the sample. And then there is the citrate concentration.

SPEAKER_01 13:01

Oh, right. The citrate.

SPEAKER_00 13:03

Yeah, so the collection tubes use citrate to bind calcium, which prevents the blood from clotting before the lab can test it.

SPEAKER_01 13:09

So it stays liquid.

SPEAKER_00 13:11

Right. If the phlebotomist doesn't fill the tube to the exact required volume, the ratio of citrate to calcium is thrown off entirely.

SPEAKER_01 13:18

And we are talking tiny amounts here.

SPEAKER_00 13:21

Tiny. That simple mechanical error alters the functional assays. A perfectly healthy patient can present with a lab profile mimicking a severe bleeding disorder simply because the collection tube was underfilled by a millimeter.

SPEAKER_01 13:33

That is terrifying when you consider that surgeries could be delayed or, you know, unnecessary treatments could be given based on a poorly filled plastic tube.

SPEAKER_00 13:41

It happens.

SPEAKER_01 13:42

And the vulnerability of the data gets even worse when you look at the traditional assays themselves, because for decades the standard was the ristacetin cofactor assay or vwf.arco.

SPEAKER_00 13:52

Right, the arco. And the medical field is finally shifting away from the ristacetin assay because of its severe vulnerability to false lows.

SPEAKER_01 14:00

Right. A false low meaning the test makes it look like the patient's blood cannot clot properly, even though physiologically, inside their own blood vessels, everything works perfectly.

SPEAKER_00 14:09

Exactly.

SPEAKER_01 14:10

It is like using a faulty speedometer that says you are driving 20 miles per hour when you are actually doing 50. The ristacetin test creates the illusion of disease right on that tricky 30 to 50 boundary line.

SPEAKER_00 14:22

And that illusion stems directly from how ristacetin interacts with the VWF protein in the test tube.

SPEAKER_01 14:28

Right, because ristacetin isn't even a human chemical, is it?

SPEAKER_00 14:31

No, it isn't. So harmless genetic sequence variants in a patient's DNA can change the shape of the protein just enough that the ristacetin chemical can't bind to it in the lab. The machine reads this as a functional defect, but in the human body, ristacetin doesn't exist.

SPEAKER_01 14:47

Right, so the patient is fine.

SPEAKER_00 14:49

The patient's VWF binds to their own platelets perfectly fine. So the modern laboratory guidelines strongly recommend newer platelet-dependent assays.

SPEAKER_01 14:59

Like the GPI binding ones?

SPEAKER_00 15:00

Exactly. Specifically the GPI binding assays like GPIBR and GPIBM, because they bypass this specific chemical limitation.

SPEAKER_01 15:08

Which proves why doctors can't just blindly follow a guideline just because it is the quote-unquote new rule. When a clinician understands why the guideline prefers the new test, you know, that it prevents a harmless genetic quirk from being misdiagnosed as a chronic disease, they become far better at evaluating the actual results.

SPEAKER_00 15:25

Exactly. You have this continuously fluctuating biology colliding with highly sensitive lab tests that can be ruined by a cold transit van, all governed by fiercely debated guidelines weighing the psychology of disease labels.

SPEAKER_01 15:37

It is a lot.

SPEAKER_00 15:38

It is a lot. To see what it looks like when all these complex moving parts converge in one single human life, we can examine a longitudinal case study.

SPEAKER_01 15:46

Let's do that. Let's look at the case of the 67-year-old woman.

SPEAKER_00 15:49

Okay.

SPEAKER_01 15:50

So she was officially diagnosed with type 1 VWD decades ago at age 24. Her historical phenotype was just undeniable. She had a severe clinical bleeding history. We are talking lifelong heavy periods, epistaxes, and prolonged bleeding after dental extractions.

SPEAKER_00 16:08

And her lab values at age 24 corroborated her phenotype. Her VWF levels were sitting low, ranging from 24 to 31.

SPEAKER_01 16:16

Solidly in the disease range.

SPEAKER_00 16:18

Right. She's diagnosed, and she was successfully managed with desmopressin for years.

SPEAKER_01 16:26

Oh, how does it work then?

SPEAKER_00 16:27

It forces the endothelial cells to temporarily flush their stored up VWF reserves into the bloodstream, raising her levels just enough to manage acute bleeding events.

SPEAKER_01 16:36

Got it. So she lived her life, she managed her bleeding, and now, 43 years later, she is 67 and requires a major surgery. Right. Her doctors run a standard preoperative lab panel, but because VWF levels naturally increase as we age, her blood tests come back completely normalized.

SPEAKER_00 16:53

Completely normal.

SPEAKER_01 16:54

Yeah. Her levels are sitting at 78 and 74. On paper today, she looks like she has absolutely no bleeding disorder at all.

SPEAKER_00 17:01

None.

SPEAKER_01 17:01

So here is the ultimate test of the compass versus the GPS. Does she still have VWD? When the surgical team preps her for the operating room, do they treat her like a patient with a bleeding disorder, or do they treat her based on her current entirely normal lab results?

SPEAKER_00 17:18

This scenario is exactly where clinical reasoning has to bridge the gap between evidence and human reality. The 2021 International Diagnosis Guideline explicitly addresses aging.

SPEAKER_01 17:30

What do they say?

SPEAKER_00 17:30

It instructs clinicians to reconsider rather than automatically remove the diagnosis when levels normalize.

SPEAKER_01 17:35

Reconsider, not remove. The word choice there is doing a lot of heavy lifting.

SPEAKER_00 17:39

It really is. It acts as a cognitive guardrail. The guideline reminds the clinician not to erase the patient's past. Her historical diagnosis at age 24 was valid.

SPEAKER_01 17:48

Right. She really did bleed.

SPEAKER_00 17:49

The old lab tests were reproducible. Her bleeding phenotype was severe and real, and her physiological response to desmopressin was well documented. You do not strip the VWD label from her medical chart just because she got older.

SPEAKER_01 18:03

But practically speaking, I mean, you also can't give her the exact same heavy-duty bleeding prophylaxis you gave her when she was 24.

SPEAKER_00 18:10

And you shouldn't. While her diagnosis remains in her chart, her surgical preparation must be adapted to her current age-adjusted biology.

SPEAKER_01 18:18

Because she is 67 now.

SPEAKER_00 18:20

Right. The clinician has to calculate the specific bleeding risk of the planned surgery against her normalized VWF levels. Crucially, they also have to factor in her new thrombosis risk. At 67 years old, the physiological risk of developing a deadly blood clot during surgery is drastically higher than it was when she was 24.

SPEAKER_01 18:40

So if a doctor rigidly followed her historical chart from 40 years ago and just heavily medicated her to prevent bleeding, they could easily cause a catastrophic blood clot. Exactly. But if they rigidly followed today's lab printout and ignored her history, she might hemorrhage on the operating table.

SPEAKER_00 18:55

The guideline doesn't make the decision for the surgeon. It simply points out where the clinician still needs to do the cognitive work. It forces the integration of the past phenotype with the present biology to keep the patient safe today.

SPEAKER_01 19:08

It perfectly illustrates that medical guidelines are not instruction manuals designed to replace human judgment.

SPEAKER_00 19:14

No, they aren't.

SPEAKER_01 19:15

They exist to make medical judgment more disciplined, more transparent, and more defensible. When a clinician looks at health data, they must verify the lived phenotype, they must question the physical conditions of the lab test, and they have to honor the patient's unique history.

SPEAKER_00 19:31

A guideline simply narrows the field of uncertainty. The human being interpreting it still has to actually walk through the forest.

SPEAKER_01 19:39

Which leaves us with an incredible concept to mull over as we wrap up. We've seen how a patient's biology, their circulating BWF levels, is a constantly moving target across their entire lifetime.

SPEAKER_00 19:50

Oh, absolutely.

SPEAKER_01 19:51

And we've seen how clinical guidelines continually rewrite themselves to try and chase that biology. As we move deeper into an era of personalized medicine, you know, equipped with continuous biometric monitoring and real-time data, are we heading toward a future where static medical guidelines become entirely obsolete?

SPEAKER_00 20:10

That is a fascinating question.

SPEAKER_01 20:12

Will a point in time lab test drawn from a plastic tube eventually be replaced by a lifelong continuous biological movie of your health? Well, until we have that continuous movie, we will always need the compass. Thank you so much for joining us on this deep dive. Keep asking questions, keep looking at the bigger picture, and we will catch you next time.